Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas
Julio Arevalo-Perez
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorAmanuel A. Kebede
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorKyung K. Peck
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorEli Diamond
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorAndrei I. Holodny
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorMarc Rosenblum
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorJennifer Rubel
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorJoshua Gaal
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorCorresponding Author
Vaios Hatzoglou
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY
Correspondence: Address correspondence to Vaios Hatzoglou, M.D. Department of Radiology Memorial Sloan Kettering Cancer Center, 1275 York Avenue New York, NY 10065. E-mail: [email protected]Search for more papers by this authorJulio Arevalo-Perez
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorAmanuel A. Kebede
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorKyung K. Peck
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorEli Diamond
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorAndrei I. Holodny
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorMarc Rosenblum
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorJennifer Rubel
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorJoshua Gaal
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Search for more papers by this authorCorresponding Author
Vaios Hatzoglou
Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY
Correspondence: Address correspondence to Vaios Hatzoglou, M.D. Department of Radiology Memorial Sloan Kettering Cancer Center, 1275 York Avenue New York, NY 10065. E-mail: [email protected]Search for more papers by this authorGrant support: Julio Arevalo-Perez was supported by a grant from the Spanish foundation “Fundación Alfonso Martín Escudero.” This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.
ABSTRACT
BACKGROUND AND PURPOSE
Low-grade and anaplastic oligodendrogliomas are often difficult to differentiate on the basis of conventional MR imaging characteristics. Dynamic contrast-enhanced (DCE) MRI can assess tumor microvasculature and has demonstrated utility for predicting glioma grade and prognosis in primary brain tumors. The aim of our study was to evaluate the performance of plasma volume (Vp) and volume transfer coefficient (Ktrans) derived from DCE MRI in differentiating between grade II and grade III oligodendrogliomas.
MATERIALS AND METHODS
Twenty-four consecutive patients with pathologically confirmed oligodendroglioma (World Health Organization grade II, n = 14 and grade III, n = 10) were retrospectively assessed. Pretreatment DCE MRI was performed and regions of interest were manually drawn around the entire tumor volume to calculate Vp and Ktrans. The Mann-Whitney U test and receiver operating characteristic (ROC) analysis were performed to compare pharmacokinetic parameters between the 2 groups.
RESULTS
The Vpmean values for grade III oligodendrogliomas were significantly higher (P = .03) than those for grade II oligodendrogliomas. The Ktransmean values were higher in grade III lesions, but the difference between the 2 groups was not statistically significant (P > .05). Based on ROC analysis, the Vpmean (area under curve = .757, SD = .1) cut-off value that provided the best combination of high sensitivity and specificity to distinguish between grade II and III oligodendrogliomas was 2.35 (P < .03).
CONCLUSION
The results of our study suggest the DCE MRI parameter Vpmean can noninvasively differentiate between grade II and grade III oligodendrogliomas.
References
- 1Chawla S, Krejza J, Vossough A, et al. Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy. AJNR Am J Neuroradiol 2013; 34: 1542-49.
- 2Bromberg JE, van den Bent MJ. Oligodendrogliomas: molecular biology and treatment. Oncologist 2009; 14: 155-63.
- 3Le Rhun E, Taillibert S, Chamberlain MC. Anaplastic glioma: current treatment and management. Expert Rev Neurother 2015; 15: 601-20.
- 4Forst DA, Nahed BV, Loeffler JS, et al. Low-grade gliomas. Oncologist 2014; 19: 403-13.
- 5Field M, Witham TF, Flickinger JC, et al. Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsy. J Neurosurg 2001; 94: 545-51.
- 6Kreth FW, Muacevic A, Medele R, et al. The risk of haemorrhage after image guided stereotactic biopsy of intra-axial brain tumours–a prospective study. Acta Neurochir 2001; 143: 539-45; discussion 45-46.
- 7Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. Am J Neuroradiol 2004; 25: 746-55.
- 8Ginsberg LE, Fuller GN, Hashmi M, et al. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998; 49: 436-40.
- 9Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999; 211: 791-98.
- 10Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004; 25: 214-21.
- 11Xu M, See SJ, Ng WH, et al. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005; 56: 919-26; discussion -26.
- 12Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24: 1989-98.
- 13Jung SC, Yeom JA, Kim JH, et al. Glioma: application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading. AJNR Am J Neuroradiol 2014; 35: 1103-10.
- 14Arevalo-Perez J, Peck KK, Young RJ, et al. Dynamic contrast-enhanced perfusion MRI and diffusion-weighted imaging in grading of gliomas. J Neuroimaging 2015; 25: 792–98.
- 15Kickingereder P, Sahm F, Wiestler B, et al. Evaluation of microvascular permeability with dynamic contrast-enhanced MRI for the differentiation of primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation. AJNR Am J Neuroradiol 2014; 35: 1503-8.
- 16Nguyen TB, Cron GO, Mercier JF, et al. Preoperative prognostic value of dynamic contrast-enhanced MRI-derived contrast transfer coefficient and plasma volume in patients with cerebral gliomas. AJNR Am J Neuroradiol 2015; 36: 63-69.
- 17Chan AS, Leung SY, Wong MP, et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 1998; 22: 816-26.
- 18Chaudhry IH, O'Donovan DG, Brenchley PE, et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001; 39: 409-15.
- 19Cha S, Johnson G, Wadghiri YZ, et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 2003; 49: 848-55.
- 20Maia AC, Jr, Malheiros SM, da Rocha AJ, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005; 26: 777-83.
- 21Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994; 191: 41-51.
- 22Aronen HJ, Pardo FS, Kennedy DN, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000; 6: 2189-2200.
- 23Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998; 171: 1479-86.
- 24Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86-91.
- 25Kapoor GS, Gocke TA, Chawla S, et al. Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol 2009; 92: 373-86.
- 26Fellah S, Caudal D, De Paula AM, et al. Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR Am J Neuroradiol 2013; 34: 1326-33.
- 27Whitmore RG, Krejza J, Kapoor GS, et al. Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 2007; 107: 600-609.
- 28Spampinato MV, Smith JK, Kwock L, et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007; 188: 204-12.
- 29Jenkinson MD, Smith TS, Joyce KA, et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006; 48: 703-13.
- 30Hilario A, Ramos A, Perez-Nunez A, et al. The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. AJNR Am J Neuroradiol 2012; 33: 701-707.
- 31Khalid L, Carone M, Dumrongpisutikul N, et al. Imaging characteristics of oligodendrogliomas that predict grade. AJNR Am J Neuroradiol 2012; 33: 852-57.
- 32Ellingson BM, Zaw T, Cloughesy TF, et al. Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas. JMRI J Magn Reson Imaging 2012; 35: 1472-77.
- 33Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006; 27: 859-67.
- 34Calamante F, Vonken EJ, van Osch MJ. Contrast agent concentration measurements affecting quantification of bolus-tracking perfusion MRI. Magn Reson Med 2007; 58: 544-53.
- 35Boxerman JL, Prah DE, Paulson ES, et al. The role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard. AJNR Am J Neuroradiol 2012; 33: 1081-87.
- 36Hacklander T, Reichenbach JR, Modder U. Comparison of cerebral blood volume measurements using the T1 and T2* methods in normal human brains and brain tumors. J Comput Assist Tomogr 1997; 21: 857-66.
- 37Alcaide-Leon P, Pareto D, Martinez-Saez E, et al. Pixel-by-pixel comparison of volume transfer constant and estimates of cerebral blood volume from dynamic contrast-enhanced and dynamic susceptibility contrast-enhanced MR imaging in high-grade gliomas. AJNR Am J Neuroradiol 2015; 36: 871-76.
- 38Awasthi R, Rathore RK, Soni P, et al. Discriminant analysis to classify glioma grading using dynamic contrast-enhanced MRI and immunohistochemical markers. Neuroradiology 2012; 54: 205-13.
- 39Jia Z, Geng D, Xie T, et al. Quantitative analysis of neovascular permeability in glioma by dynamic contrast-enhanced MR imaging. J Clin Neurosci 2012; 19: 820-23.
- 40Mills SJ, Soh C, O'Connor JP, et al. Enhancing fraction in glioma and its relationship to the tumoral vascular microenvironment: a dynamic contrast-enhanced MR imaging study. AJNR Am J Neuroradiol 2010; 31: 726-31.
- 41Jia Z, Geng D, Liu Y, et al. Low-grade and anaplastic oligodendrogliomas: differences in tumour microvascular permeability evaluated with dynamic contrast-enhanced magnetic resonance imaging. J Clin Neurosci 2013; 20: 1110-13.
- 42Alcaide-Leon P, Rovira A. Dynamic contrast-enhanced MR: importance of reaching the washout phase. AJNR Am J Neuroradiol 2013; 34: E58-E59.
- 43Rathore RK, Gupta RK. Dynamic contrast-enhanced MR: importance of reaching the washout phase. Author reply. AJNR Am J Neuroradiol 2013; 34: E60.
- 44Guo JY, Reddick WE, Rosen MA, et al. Dynamic contrast-enhanced magnetic resonance imaging parameters independent of baseline T10 values. Magn Reson Imaging 2009; 27: 1208-15.
- 45Haacke EM, Filleti CL, Gattu R, et al. New algorithm for quantifying vascular changes in dynamic contrast-enhanced MRI independent of absolute T1 values. Magn Reson Med 2007; 58: 463-72.
Citing Literature
